#### Triple Artemisinin-based Combination Therapy

Artemisin-based combination therapies are losing their **efficacy ** due to an emerging **resistance** of malaria parasites. **TACT ** is an alternative treatment where an artemisinin derivative, e.g. dihydroartemisinin (**DHA**), is combined with two partner drugs, e.g. piperaquine (**PPQ**) and mefloquine (**MQ**), to overcome this threat.

We have developed a **within-host mathematical model** that allows us to simulate the pharmacokinetics and pharmacodynamics underpinning the drugs-parasites interactions.

Learn more here …

#### Efficacy Analysis of DSM265

**Medicines for Malaria Ventures (MMV)** is currently using simple PKPD models to describe the pharmacological behavior of candidate antimalarials, such as **DSM265**, where the parasites killing rate of a drug is linked to its concentration by a sigmoidal Emax model. This type of model has the advantage of having only a few parameters and it is thus possible to estimate these from rather limited information. However, for some compounds, these models do not describe well the observed trends unless the dose is included as a covariate on Emax or EC50. A hypothesis is that it is due to the killing rate of these drugs being dependent on the stages of the parasites and is thus not well represented by the simple models used since they assume a uniform killing rate of the drug across the lifecycle of the parasites.

We have developed a **within-host mathematical model** that allows us to simulate the pharmacokinetics and pharmacodynamics underpinning the drugs-parasites interactions.

Learn more here …